A recent pre-clinical study suggested that a second-generation therapeutic CXCR4 ligand, [177Lu]DOTA-r-a-ABA-CPCR4, may provide even better targeting efficiency and tumor retention than [177Lu]Pentixather 38. This evidence concerns the gene CXCR4 and neoplasm.